Aktienanalyse zu Oramed Pharmaceuticals Inc (ORMP)ORMPOramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Oramed Pharmaceuticals Inc is currently trading at $4, which is 56.5% of its 52-week range, indicating it is closer to its 52-week high of $5.47. However, the RSI is at a low 29.89, suggesting the stock is oversold. The company reported a profit of $10 million in Q4, translating to an EPS of $0.24, which reflects strong profitability despite low revenue. The main risk is the significant drop in revenue with total revenue reported as $2 million in Q1 2025 and a projected earnings surprise of -120.93% in the last earnings report, indicating potential volatility ahead.

2 analysts cover ORMP: 2 rate it Buy, 0 Hold and 0 Sell.